Abstract
Background
Patients on chronic hemodialysis (HD) have an increased incidence of malignancy due to decreased immunity. Soluble interleukin-2 receptor (sIL-2R), as an immunomodulator, seemed to have an effect in the process of malignancy. In this study, we aimed to evaluate the clinical significance of increased sIL-2R in the course of malignancy among HD patients.
Methods
Patients who undergoing chronic hemodialysis were followed for 24 months. Risk factors for malignancy events and malignancy-related mortality during the 2-year follow-up period were investigated among various clinicopathological variables.
Results
Of the 363 patients included in this research, 47 patients (12.95%) had a prior history of treated malignancy. During the 2-year follow-up period, malignancy events were detected in 15 (4.12%) patients. Sixty-seven patients died during the study period, of which nine patients (13.43%) were died of malignancy. Malignancy events reduced 2-year mortality significantly (log-rank = 23.02, P < 0.0001). Both high sIL-2R levels ( ≥ 2-fold upper limit of the normal value) (OR 6.6, P = 0.006) and a prior history of treated malignancy (OR 4.12, P = 0.018)were identified by multivariate logistic analysis as independent determinants for malignancy events. However, only the levels of sIL-2R (used as a continuous variable) had the significantly predictive effect on malignancy events and malignancy-related mortality in the following 2 years.
Conclusions
Elevated sIL-2R levels was commonly seen in serum of HD patients. And this elevated level increased the risk of malignancy. Aside from its role as a biomarker, sIL-2R may also exert biological effects in the course of malignancy.
Similar content being viewed by others
Abbreviations
- IL-2:
-
Interleukin-2
- IL-2R:
-
Interleukin-2 receptor
- sIL-2R:
-
Soluble interleukin-2 receptor
- HD:
-
Hemodialysis
- ESRD:
-
End-stage renal disease
- CVD:
-
Cardiovascular disease
- BMI:
-
Body-mass index
- ESA:
-
Erythropoietin-stimulating agent
- spKt/V:
-
Single-pooled Kt/V
- TNF-α:
-
Tumor necrosis Factor α
- RDW:
-
Red blood cell distribution width
- hsCRP:
-
High-sensitivity C-reactive protein
- AKP:
-
Alkaline phosphatase
- GGT:
-
γ-Glutamyl transferase
- LDH:
-
Lactate dehydrogenase
- SCr:
-
Serum creatinine
- UA:
-
Uric acid
- β2-MG:
-
Beta-2-microglobulin
- iPTH:
-
Intact parathyroid hormone
- HbA1c:
-
Glycosylated hemoglobin
- SD:
-
Standard deviation
- IQR:
-
Interquartile range
- ROC:
-
Receiver operating characteristic
- OR:
-
Odds ratio
- CI:
-
Confidence interval
References
Chien CC, Han MM, Chiu YH et al (2017) Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer 8(1):9–18. https://doi.org/10.7150/jca.16550
Cheung CY, Chan GC, Chan SK et al (2016) Cancer incidence and mortality in chronic dialysis population: a multicenter cohort study. Am J Nephrol 43(3):153–159. https://doi.org/10.1159/000445362
Butler AM, Olshan AF, Kshirsagar AV et al (2015) Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis 65(5):763–772. https://doi.org/10.1053/j.ajkd.2014.12.013
Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (London, England) 354(9173):93–99
Vamvakas S, Bahner U, Heidland A (1998) Cancer in end-stage renal disease: potential factors involved—editorial. Am J Nephrol 18(2):89–95. https://doi.org/10.1159/000013314
Bayer AL, Pugliese A, Malek TR (2013) The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res 57(1–3):197–209. https://doi.org/10.1007/s12026-013-8452-5
Bien E, Balcerska A (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers Biochem Indic Expo Response Susceptibility Chem 13(1):1–26. https://doi.org/10.1080/13547500701674063
Rubin LA, Kurman CC, Fritz ME et al (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (Baltimore, Md: 1950) 135(5):3172–3177
Memoli B, Libetta C, De Nicola L et al (1996) Hemodialysis related interleukin-2 receptor release by peripheral blood mononuclear cells. ASAIO J (Am Soc Artif Intern Org: 1992) 42(1):60–63
Daichou Y, Kurashige S, Hashimoto S et al (1999) Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 83(3):237–245
Beaurain G, Naret C, Marcon L et al (1989) In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 36(4):636–644
Sennesael JJ, Demanet CG, Verbeelen DL (1995) Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin. Blood Purif 13(6):347–356. https://doi.org/10.1159/000170219
Mehta R, Shah G, Adler W et al (2004) Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients. Clin Transpl 18(Suppl 12):67–71. https://doi.org/10.1111/j.1399-0012.2004.00221.x
Shu KH, Lu YS, Cheng CH et al (1998) Soluble interleukin 2 receptor in dialyzed patients. Artif Org 22(2):142–144
Holtkamp W, Brodersen HP, Stollberg T et al (1993) Zinc supplementation stimulates tetanus antibody formation and soluble interleukin-2 receptor levels in chronic hemodialysis patients. Clin Investig 71(7):537–541
Ding X (2016) SIKD is on the road. Blood Purif 42(1):I–vi. https://doi.org/10.1159/000442281
Cao XS, Chen J, Zou JZ et al (2015) Association of indoxyl sulfate with heart failure among patients on hemodialysis. Clin J Am Soc Nephrol 10(1):111–119. https://doi.org/10.2215/cjn.04730514
Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol JASN 4(5):1205–1213
Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338
Chen WQ, Zheng RS, Zeng HM et al (2012) Trend analysis and prediction of cancer incidence in China. Zhonghua yu fang yi xue za zhi [Chin J Prev Med] 46(7):581–586
Matas A, Simmons R, Kjellstrand C et al (1975) Increased incidence of malignancy during chronic renal failure. Lancet (London, England) 1(7912):883–886
Cengiz K (2002) Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 33(1):121–126
Lin HF, Li YH, Wang CH et al (2012) Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transpl 27(4):1585–1590. https://doi.org/10.1093/ndt/gfr464
Wong G, Staplin N, Emberson J et al (2016) Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer 16:488. https://doi.org/10.1186/s12885-016-2532-6
Yoo KD, Lee JP, Lee SM et al (2017) Cancer in Korean patients with end-stage renal disease: a 7-year follow-up. PLoS ONE 12(7):e0178649. https://doi.org/10.1371/journal.pone.0178649
Igney FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71(6):907–920
Poggi A, Zocchi MR (2006) Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp 54(5):323–333. https://doi.org/10.1007/s00005-006-0038-7
Chouaib S, Thiery J, Gati A et al (2002) Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 60(4):273–281
Xiang FF, Zhu JM, Cao XS et al (2016) Lymphocyte depletion and subset alteration correlate to renal function in chronic kidney disease patients. Ren Fail 38(1):7–14. https://doi.org/10.3109/0886022x.2015.1106871
Xiang F, Chen R, Cao X et al (2018) Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study. Hemodial Int Int Symp Home Hemodial 22(1):82–92. https://doi.org/10.1111/hdi.12549
Guo M, Chen R, Xiang F et al (2018) Decreased percentage of memory B cells is independently associated with increased susceptibility to infection in patients on maintenance hemodialysis. Int Urol Nephrol. https://doi.org/10.1007/s11255-018-1977-8
Chen R, Xiang F, Hu J et al (2017) Factors associated with the elevated percentage of CD4CD69 T cells in maintained hemodialysis patients. Ren Fail 39(1):547–554. https://doi.org/10.1080/0886022x.2017.1349672
Descamps-Latscha B, Herbelin A, Nguyen AT et al (1995) Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis Relationships with activation markers of T cells, B cells, and monocytes. J Immunol (Baltimore, Md: 1950) 154(2):882–892
Chatenoud L, Dugas B, Beaurain G et al (1986) Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci USA 83(19):7457–7461
Schiffl H, Lang SM, Stratakis D et al (2001) Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transpl 16(9):1863–1869
Debeljak N, Solar P, Sytkowski AJ (2014) Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol 5:563. https://doi.org/10.3389/fimmu.2014.00563
Fentiman IS (2012) Gamma-glutamyl transferase: risk and prognosis of cancer. Br J Cancer 106(9):1467–1468. https://doi.org/10.1038/bjc.2012.128
Nakase K, Tsuji K, Tamaki S et al (2005) Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev 29(3):256–259. https://doi.org/10.1016/j.cdp.2005.03.001
Nakase K, Kita K, Nasu K et al (1994) Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 46(3):179–183
Nakase K, Kita K, Shirakawa S et al (1994) Induction of cell surface interleukin 2 receptor alpha chain expression on non-T lymphoid leukemia cells. Leuk Res 18(11):855–859
Rimoldi D, Salvi S, Hartmann F et al (1993) Expression of IL-2 receptors in human melanoma cells. Anticancer Res 13(3):555–564
Yano T, Fukuyama Y, Yokoyama H et al (1996) Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer (Amst, Neth) 16(1):13–19
Wang LS, Chow KC, Li WY et al (2000) Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clin Cancer Res 6(4):1445–1451
Huang A, Quinn H, Glover C et al (2002) The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation. Cancer Immunol Immunother CII 51(1):53–57. https://doi.org/10.1007/s00262-001-0250-6
De Paiva CS, Yoon KC, Pangelinan SB et al (2009) Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelia by MMP-9. J Inflamm (Lond, Engl) 6:31. https://doi.org/10.1186/1476-9255-6-31
Berghella AM, Pellegrini P, Piancatelli D et al (1994) Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother CII 38(3):160–166
Murakami S (2004) Soluble interleukin-2 receptor in cancer. Front Biosci J Virtual Libr 9:3085–3090
Kobayashi H, Tagaya Y, Han ES et al (1999) Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. Cytokine 11(12):1065–1075. https://doi.org/10.1006/cyto.1999.0509
Wang X, Rickert M, Garcia KC (2005) Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science (New York, NY) 310(5751):1159–1163. https://doi.org/10.1126/science.1117893
Yang ZZ, Grote DM, Ziesmer SC et al (2011) Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118(10):2809–2820. https://doi.org/10.1182/blood-2011-03-340885
Brivio F, Lissoni P, Fumagalli L et al (2008) Correlation between soluble IL-2 receptor serum levels and regulatory T lymphocytes in patients with solid tumors. Int J Biol Mark 23(2):121–122
Kasprzak A, Olejniczak K, Przybyszewska W et al (2007) Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol 66(3):159–166
Kuhn DJ, Dou QP (2005) The role of interleukin-2 receptor alpha in cancer. Front Biosci J Virtual Libr 10:1462–1474
Nukui A, Masuda A, Abe H et al (2017) Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy. BMC Cancer 17(1):372. https://doi.org/10.1186/s12885-017-3369-3
Zaoui P, Green W, Hakim RM (1991) Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 39(5):1020–1026
Funding
This study was founded by Shanghai Clinical Medical Center for Kidney Disease Project support by Shanghai Municipal Health Commission (no. 2017ZZ01015) and Shanghai Municipal Hospital Frontier Technology Project supported by Shanghai ShenKang Hospital Development Center (no. SHDC12018127).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We declare no conflict of interest.
Informed consent
Informed consents were obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
XiaoHong, C., Bo, S., FangFang, X. et al. Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis. Int J Clin Oncol 24, 1151–1160 (2019). https://doi.org/10.1007/s10147-019-01455-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-019-01455-5